SIMILAR PATTERNS OF AMINO ACIDS FOR 2Y7J_B_B49B1294

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.55A	2y7jB-1k2pA: 19.9	2y7jB-1k2pA: 22.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321	None	0.53A	2y7jB-1k9aA: 26.1	2y7jB-1k9aA: 23.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 MET A 269 LEU A 321 ASP A 332	None	0.82A	2y7jB-1k9aA: 26.1	2y7jB-1k9aA: 23.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	7	ILE A 580 VAL A 588 ALA A 606 PHE A 654 MET A 657 GLY A 660 LEU A 731	None	0.92A	2y7jB-1lufA: 24.6	2y7jB-1lufA: 24.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	ILE A 211 VAL A 219 ALA A 230 GLY A 286 LEU A 340 ASP A 351	PY1 A 700 (-3.6A) PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.6A) PY1 A 700 (-4.4A) PY1 A 700 (-2.7A)	0.53A	2y7jB-1py5A: 18.8	2y7jB-1py5A: 24.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ILE A 369 VAL A 377 ALA A 389 PHE A 435 MET A 438 GLY A 441 LEU A 489 ASP A 500	None	0.83A	2y7jB-1snxA: 24.3	2y7jB-1snxA: 22.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 ILE A 89 GLY A 110 LEU A 158	None	0.54A	2y7jB-1u5qA: 30.0	2y7jB-1u5qA: 25.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 ILE A 89 LEU A 158 ASP A 169	None	0.80A	2y7jB-1u5qA: 30.0	2y7jB-1u5qA: 25.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 26 ALA A 39 ILE A 75 PHE A 91 MET A 94 LEU A 144	ATP A 381 (-4.0A) ATP A 381 (-3.6A) None None None None	0.55A	2y7jB-1ua2A: 23.3	2y7jB-1ua2A: 26.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 98 ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.63A	2y7jB-2ac5A: 20.5	2y7jB-2ac5A: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 27 ALA A 40 ILE A 72 LEU A 95 MET A 96 LEU A 144	ADP A 500 (-4.3A) ADP A 500 ( 3.7A) None ADP A 500 ( 4.9A) None ADP A 500 (-4.3A)	0.27A	2y7jB-2f9gA: 20.6	2y7jB-2f9gA: 25.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 ILE A 89 GLY A 110 LEU A 158	STU A 400 (-4.2A) STU A 400 ( 4.8A) STU A 400 (-3.2A) STU A 400 ( 4.5A) STU A 400 (-3.4A) STU A 400 ( 4.6A)	0.56A	2y7jB-2gcdA: 31.2	2y7jB-2gcdA: 23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	ILE A 635 VAL A 643 ALA A 659 ILE A 691 MET A 710 GLY A 713 LEU A 761	ADP A 400 (-4.9A) ADP A 400 ( 4.4A) ADP A 400 (-3.2A) None None ADP A 400 ( 4.2A) ADP A 400 ( 4.7A)	0.64A	2y7jB-2henA: 13.4	2y7jB-2henA: 20.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LEU A 501 GLY A 505 LEU A 553	4ST A1687 (-4.2A) 4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-4.3A) 4ST A1687 (-3.2A) 4ST A1687 (-4.4A)	0.60A	2y7jB-2j0jA: 24.6	2y7jB-2j0jA: 19.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LEU A 501 GLY A 505 LEU A 553	BII A1687 (-3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) BII A1687 (-4.4A) BII A1687 (-3.6A) BII A1687 (-4.2A)	0.69A	2y7jB-2jkmA: 24.4	2y7jB-2jkmA: 22.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	8	VAL A 33 ALA A 46 ILE A 87 PHE A 103 LEU A 105 MET A 106 GLY A 109 LEU A 156	ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None None None None ATP A 381 ( 4.8A)	0.28A	2y7jB-2phkA: 38.1	2y7jB-2phkA: 53.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 495 ALA A 515 ILE A 548 GLY A 570 LEU A 633 ASP A 644	None	0.65A	2y7jB-2psqA: 27.1	2y7jB-2psqA: 24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	ILE B 47 VAL B 55 ALA B 67 MET B 117 GLY B 120 LEU B 171	None	0.42A	2y7jB-2qkwB: 25.7	2y7jB-2qkwB: 27.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 ILE A 683 MET A 702 GLY A 705 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None PTR A 701 ( 3.5A) None None	0.59A	2y7jB-2qobA: 20.0	2y7jB-2qobA: 20.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ILE A 681 VAL A 689 ALA A 705 ILE A 737 MET A 756 GLY A 759 LEU A 807	None	0.78A	2y7jB-2r2pA: 27.3	2y7jB-2r2pA: 21.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 732 ALA A 749 LEU A 798 MET A 799 GLY A 802 LEU A 850	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-4.5A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.59A	2y7jB-2r4bA: 23.1	2y7jB-2r4bA: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vuw	SERINE/THREONINE-PRO TEIN KINASE HASPIN (Homo sapiens)	PF12330 (Haspin_kinase)	6	ILE A 490 VAL A 498 ALA A 509 ILE A 557 PHE A 605 LEU A 656	None 5ID A1800 ( 4.5A) 5ID A1800 (-3.4A) 5ID A1800 ( 4.5A) 5ID A1800 (-4.1A) 5ID A1800 (-4.5A)	0.49A	2y7jB-2vuwA: 18.9	2y7jB-2vuwA: 22.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2wnt	RIBOSOMAL PROTEIN S6 KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 424 ALA A 445 ILE A 473 LEU A 491 MET A 492 ASP A 557	None	0.78A	2y7jB-2wntA: 26.1	2y7jB-2wntA: 32.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 234 ALA A 247 ILE A 286 LEU A 303 MET A 304 GLY A 307 LEU A 354	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) None XK9 A1511 (-4.1A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A)	0.37A	2y7jB-2xk9A: 29.5	2y7jB-2xk9A: 31.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	7	ILE A 627 VAL A 635 ALA A 651 ILE A 683 MET A 702 GLY A 705 LEU A 753	None Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 ( 4.9A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.58A	2y7jB-2xyuA: 18.8	2y7jB-2xyuA: 22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1010 ALA A1028 LEU A1078 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-4.7A) None S91 A 1 (-3.3A) None	0.71A	2y7jB-2z8cA: 26.9	2y7jB-2z8cA: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 495 ALA A 515 ILE A 548 GLY A 570 LEU A 633 ASP A 644	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None M33 A1996 ( 4.8A) M33 A1996 (-4.5A) M33 A1996 (-4.0A)	0.43A	2y7jB-3b2tA: 22.8	2y7jB-3b2tA: 22.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 18 VAL A 26 ALA A 39 PHE A 91 MET A 94 LEU A 148	3AM A 338 (-4.5A) 3AM A 338 ( 4.1A) 3AM A 338 (-3.3A) 3AM A 338 (-3.6A) None 3AM A 338 (-4.7A)	0.77A	2y7jB-3c0iA: 32.8	2y7jB-3c0iA: 28.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 492 ALA A 512 ILE A 545 GLY A 567 LEU A 630 ASP A 641	None C4F A 1 (-3.3A) C4F A 1 ( 4.0A) None C4F A 1 (-4.6A) C4F A 1 (-4.5A)	0.82A	2y7jB-3c4fA: 23.6	2y7jB-3c4fA: 24.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321	None	0.53A	2y7jB-3d7uA: 26.9	2y7jB-3d7uA: 22.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 MET A 269 LEU A 321 ASP A 332	None	0.82A	2y7jB-3d7uA: 26.9	2y7jB-3d7uA: 22.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 23 VAL A 31 ALA A 44 LEU A 94 LEU A 153 ASP A 164	ANP A 1 (-4.2A) ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None ANP A 1 (-3.8A)	0.81A	2y7jB-3dakA: 25.0	2y7jB-3dakA: 26.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ILE A 639 VAL A 647 ALA A 663 MET A 714 GLY A 717 LEU A 765	IHZ A1001 ( 4.8A) IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) None IHZ A1001 ( 3.9A) IHZ A1001 (-4.6A)	0.63A	2y7jB-3dkoA: 23.4	2y7jB-3dkoA: 21.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 150 VAL A 158 ALA A 169 ILE A 204 GLY A 226 LEU A 275	VIN A6331 (-4.0A) VIN A6331 (-4.7A) VIN A6331 (-3.4A) VIN A6331 ( 4.9A) VIN A6331 (-3.4A) VIN A6331 (-4.5A)	0.39A	2y7jB-3dtcA: 23.7	2y7jB-3dtcA: 23.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 32 VAL A 40 ALA A 53 ILE A 86 LEU A 110 MET A 111	35F A 1 ( 4.4A) 35F A 1 ( 4.8A) 35F A 1 (-3.6A) None 35F A 1 (-4.5A) None	0.39A	2y7jB-3e7oA: 24.1	2y7jB-3e7oA: 23.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f3z	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 ILE A 86 LEU A 104 LEU A 155	DRK A 1 (-4.2A) DRK A 1 ( 4.9A) DRK A 1 (-3.4A) DRK A 1 ( 4.8A) DRK A 1 (-4.4A) DRK A 1 (-4.6A)	0.59A	2y7jB-3f3zA: 35.0	2y7jB-3f3zA: 27.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	7	ALA A 247 ILE A 286 LEU A 303 MET A 304 GLY A 307 LEU A 354 ASP A 368	None	0.80A	2y7jB-3i6uA: 28.0	2y7jB-3i6uA: 30.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	7	VAL A 234 ALA A 247 ILE A 286 LEU A 303 MET A 304 LEU A 354 ASP A 368	None	0.84A	2y7jB-3i6uA: 28.0	2y7jB-3i6uA: 30.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 ILE A 697 MET A 716 GLY A 719 LEU A 767 ASP A 778	None None None None GOL A 403 (-3.4A) None None	0.93A	2y7jB-3kulA: 27.4	2y7jB-3kulA: 26.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 47 ALA A 60 ILE A 94 GLY A 116 LEU A 165 ASP A 179	QUE A 1 ( 4.6A) QUE A 1 (-3.2A) QUE A 1 (-4.6A) None None QUE A 1 (-2.9A)	0.79A	2y7jB-3lm5A: 31.9	2y7jB-3lm5A: 30.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3n9x	PHOSPHOTRANSFERASE (Plasmodium berghei)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 ILE A 88 LEU A 161 ASP A 172	GOL A 434 ( 4.5A) None GOL A 434 ( 4.1A) None GOL A 434 (-4.2A) GOL A 433 (-2.7A)	0.64A	2y7jB-3n9xA: 24.1	2y7jB-3n9xA: 24.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	VAL A 200 ALA A 213 LEU A 265 MET A 266 GLY A 269 LEU A 318	AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 ( 4.9A) None None AMP A 577 (-4.8A)	0.37A	2y7jB-3nyoA: 30.6	2y7jB-3nyoA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 734 ALA A 751 LEU A 800 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.6A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.45A	2y7jB-3pp0A: 25.4	2y7jB-3pp0A: 21.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	6	ILE A 557 VAL A 565 ALA A 576 GLY A 631 LEU A 683 ASP A 694	STU A 1 (-4.1A) STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A)	0.70A	2y7jB-3ppzA: 29.3	2y7jB-3ppzA: 28.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 492 ALA A 512 ILE A 545 GLY A 567 LEU A 630 ASP A 641	07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A) 07J A 1 (-4.7A)	0.82A	2y7jB-3tt0A: 18.0	2y7jB-3tt0A: 25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 552 ALA A 570 PHE A 617 MET A 620 GLY A 623 LEU A 686	None 0F4 A 902 (-3.2A) 0F4 A 902 (-3.4A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.37A	2y7jB-3v5qA: 18.5	2y7jB-3v5qA: 25.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 67 ALA A 80 LEU A 131 MET A 132 LEU A 186 ASP A 197	ANK A 401 (-4.3A) ANK A 401 (-3.0A) None None ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.78A	2y7jB-3vn9A: 24.1	2y7jB-3vn9A: 24.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 83 ALA A 96 MET A 147 GLY A 150 LEU A 198 ASP A 209	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.75A	2y7jB-3wigA: 19.3	2y7jB-3wigA: 23.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.64A	2y7jB-3zbfA: 21.0	2y7jB-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1959 ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.38A	2y7jB-3zbfA: 21.0	2y7jB-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ILE A 625 VAL A 633 ALA A 649 ILE A 681 MET A 700 GLY A 703 LEU A 751 ASP A 762	None	0.60A	2y7jB-3zfxA: 26.8	2y7jB-3zfxA: 22.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 568 ALA A 586 PHE A 633 MET A 636 GLY A 639 LEU A 699	None LTI A1839 (-3.3A) LTI A1839 (-3.5A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.43A	2y7jB-4at3A: 18.0	2y7jB-4at3A: 23.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ILE A 97 VAL A 105 ALA A 121 ILE A 153 MET A 172 GLY A 175 LEU A 223 ASP A 234	30K A1365 (-4.5A) 30K A1365 ( 4.6A) 30K A1365 (-3.2A) None None 30K A1365 (-3.5A) 30K A1365 (-4.5A) 30K A1365 (-3.3A)	0.63A	2y7jB-4aw5A: 20.2	2y7jB-4aw5A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b99	MITOGEN-ACTIVATED PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 61 VAL A 69 ALA A 82 ILE A 115 LEU A 139 MET A 140 LEU A 189	R4L A1394 (-4.0A) R4L A1394 (-4.0A) R4L A1394 ( 3.7A) R4L A1394 (-4.9A) R4L A1394 ( 4.9A) None R4L A1394 (-4.5A)	0.68A	2y7jB-4b99A: 26.7	2y7jB-4b99A: 25.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	6	VAL A 254 ALA A 267 ILE A 302 GLY A 324 LEU A 371 ASP A 382	None	0.77A	2y7jB-4c0tA: 29.6	2y7jB-4c0tA: 17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	ILE A 567 VAL A 575 ALA A 588 LEU A 638 GLY A 642 LEU A 690	GUI A 901 (-4.0A) GUI A 901 (-4.5A) GUI A 901 (-3.4A) GUI A 901 (-4.4A) GUI A 901 (-3.5A) GUI A 901 (-4.3A)	0.57A	2y7jB-4e93A: 20.4	2y7jB-4e93A: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 523 ALA A 541 PHE A 588 MET A 591 GLY A 594 LEU A 656	None	0.40A	2y7jB-4f0iA: 17.2	2y7jB-4f0iA: 22.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A1130 ALA A1148 LEU A1198 MET A1199 GLY A1202 LEU A1256 ASP A1270	0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.8A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A) 0UV A1501 ( 4.2A)	0.62A	2y7jB-4fodA: 24.3	2y7jB-4fodA: 23.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 29 VAL A 37 ALA A 50 LEU A 102 GLY A 106 LEU A 153	STU A 401 (-4.1A) STU A 401 ( 4.9A) STU A 401 (-3.2A) STU A 401 (-4.4A) STU A 401 ( 3.7A) STU A 401 (-4.7A)	0.57A	2y7jB-4fr4A: 29.8	2y7jB-4fr4A: 21.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ASP A 404	0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A)	0.70A	2y7jB-4k11A: 24.3	2y7jB-4k11A: 24.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 413 VAL A 421 ALA A 434 GLY A 487 LEU A 533 ASP A 544	B49 A 701 (-4.2A) None B49 A 701 (-3.2A) B49 A 701 ( 3.7A) B49 A 701 (-4.5A) B49 A 701 (-4.6A)	0.46A	2y7jB-4ks8A: 30.9	2y7jB-4ks8A: 26.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ASP A 404	VGG A 601 ( 3.5A) VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.7A)	0.40A	2y7jB-4lggA: 23.8	2y7jB-4lggA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	7	ILE A 197 VAL A 205 ALA A 218 LEU A 273 MET A 274 GLY A 276 LEU A 324	29X A 702 (-4.7A) 29X A 702 (-4.7A) 29X A 702 (-3.1A) 29X A 702 (-4.6A) None None 29X A 702 (-4.6A)	0.85A	2y7jB-4mk0A: 30.9	2y7jB-4mk0A: 20.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	7	ILE A 197 VAL A 205 ALA A 218 LEU A 273 MET A 274 LEU A 324 ASP A 335	29X A 702 (-4.7A) 29X A 702 (-4.7A) 29X A 702 (-3.1A) 29X A 702 (-4.6A) None 29X A 702 (-4.6A) 29X A 702 (-4.4A)	0.88A	2y7jB-4mk0A: 30.9	2y7jB-4mk0A: 20.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	6	ILE A 197 VAL A 205 ALA A 218 MET A 274 GLY A 277 LEU A 324	29X A 702 (-4.7A) 29X A 702 (-4.7A) 29X A 702 (-3.1A) None None 29X A 702 (-4.6A)	0.72A	2y7jB-4mk0A: 30.9	2y7jB-4mk0A: 20.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 644 ILE A 676 MET A 695 GLY A 698 LEU A 746 ASP A 757	None	0.59A	2y7jB-4p2kA: 26.9	2y7jB-4p2kA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ILE A 619 VAL A 627 ALA A 644 ILE A 676 MET A 695 GLY A 698 LEU A 746	None	0.64A	2y7jB-4p2kA: 26.9	2y7jB-4p2kA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qny	MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	6	ILE A 27 VAL A 35 ALA A 49 ILE A 83 MET A 107 LEU A 156	ANP A 402 (-4.6A) ANP A 402 (-4.3A) ANP A 402 (-3.3A) ANP A 402 (-4.8A) None ANP A 402 (-4.6A)	0.37A	2y7jB-4qnyA: 28.2	2y7jB-4qnyA: 23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qtb	MITOGEN-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 48 VAL A 56 ALA A 69 ILE A 101 LEU A 124 MET A 125 LEU A 173	38Z A 418 ( 4.4A) None 38Z A 418 (-3.4A) 38Z A 418 ( 4.9A) 38Z A 418 ( 4.8A) None 38Z A 418 (-4.4A)	0.46A	2y7jB-4qtbA: 21.1	2y7jB-4qtbA: 27.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 150 VAL A 158 ALA A 169 ILE A 204 GLY A 226 LEU A 275 ASP A 294	None	1.02A	2y7jB-4uy9A: 22.8	2y7jB-4uy9A: 23.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.68A	2y7jB-4xi2A: 23.7	2y7jB-4xi2A: 22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xrl	MITOGEN-ACTIVATED PROTEIN KINASE 1 (Rattus norvegicus)	PF00069 (Pkinase)	7	ILE A 29 VAL A 37 ALA A 50 ILE A 82 LEU A 105 MET A 106 LEU A 154	42A A 402 ( 4.7A) None 42A A 402 (-3.2A) None 42A A 402 ( 4.9A) None 42A A 402 ( 4.9A)	0.58A	2y7jB-4xrlA: 28.1	2y7jB-4xrlA: 24.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z7g	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	VAL A 586 ALA A 597 ILE A 626 LEU A 644 LEU A 695 ASP A 711	None	0.80A	2y7jB-4z7gA: 22.6	2y7jB-4z7gA: 22.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4zsl	MITOGEN-ACTIVATED PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 61 VAL A 69 ALA A 82 ILE A 115 LEU A 139 MET A 140 LEU A 189	None	0.63A	2y7jB-4zslA: 26.1	2y7jB-4zslA: 26.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 492 ALA A 512 ILE A 545 GLY A 567 LEU A 630 ASP A 641	38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.3A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) 38O A1769 (-4.0A)	0.63A	2y7jB-5a46A: 23.8	2y7jB-5a46A: 23.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5awm	STRESS-ACTIVATED PROTEIN KINASE JNK (Drosophila melanogaster)	PF00069 (Pkinase)	6	ILE A 30 VAL A 38 ALA A 51 ILE A 84 LEU A 108 MET A 109	ANP A 401 (-4.9A) ANP A 401 (-4.5A) ANP A 401 (-3.5A) None ANP A 401 ( 4.8A) None	0.46A	2y7jB-5awmA: 23.3	2y7jB-5awmA: 23.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci6	MITOGEN-ACTIVATED PROTEIN KINASE 6 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ILE A 69 VAL A 77 ALA A 90 LEU A 146 MET A 147 LEU A 196	None	0.56A	2y7jB-5ci6A: 24.7	2y7jB-5ci6A: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 22 VAL A 30 ALA A 44 GLY A 98 LEU A 145 ASP A 165	51W A 401 (-3.9A) 51W A 401 ( 4.3A) 51W A 401 (-3.4A) 51W A 401 (-3.7A) 51W A 401 (-4.5A) GOL A 404 (-3.2A)	0.79A	2y7jB-5ci7A: 26.7	2y7jB-5ci7A: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ezr	CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE (Plasmodium vivax)	PF00027 (cNMP_binding) PF00069 (Pkinase)	6	ILE A 540 VAL A 548 ALA A 561 ILE A 595 LEU A 613 ASP A 675	4ZS A 901 (-4.2A) 4ZS A 901 (-4.8A) 4ZS A 901 ( 3.8A) 4ZS A 901 (-4.3A) 4ZS A 901 (-4.7A) None	0.67A	2y7jB-5ezrA: 27.7	2y7jB-5ezrA: 18.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ezr	CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE (Plasmodium vivax)	PF00027 (cNMP_binding) PF00069 (Pkinase)	6	ILE A 540 VAL A 548 ALA A 561 ILE A 595 LEU A 613 LEU A 664	4ZS A 901 (-4.2A) 4ZS A 901 (-4.8A) 4ZS A 901 ( 3.8A) 4ZS A 901 (-4.3A) 4ZS A 901 (-4.7A) 4ZS A 901 (-3.6A)	0.51A	2y7jB-5ezrA: 27.7	2y7jB-5ezrA: 18.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	6	VAL A 28 ALA A 41 PHE A 90 LEU A 92 GLY A 96 LEU A 143	ADP A 301 (-3.7A) ADP A 301 (-3.5A) None ADP A 301 ( 4.8A) None ADP A 301 (-4.7A)	0.38A	2y7jB-5hu3A: 36.3	2y7jB-5hu3A: 34.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 726 ALA A 743 LEU A 792 MET A 793 GLY A 796 LEU A 844 ASP A 855	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 ( 4.9A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-4.3A)	0.35A	2y7jB-5j9zA: 24.9	2y7jB-5j9zA: 23.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 396 VAL A 404 ALA A 417 LEU A 467 GLY A 471 LEU A 518	GUI A 701 (-4.1A) GUI A 701 (-4.4A) GUI A 701 ( 3.9A) GUI A 701 ( 4.7A) GUI A 701 (-3.6A) GUI A 701 (-4.4A)	0.46A	2y7jB-5jznA: 35.1	2y7jB-5jznA: 31.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 155 VAL A 163 ALA A 176 ILE A 212 PHE A 228 LEU A 230 LEU A 282	7A7 A 501 ( 4.3A) 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-4.8A) 7A7 A 501 (-3.7A) None 7A7 A 501 (-4.9A)	0.84A	2y7jB-5lxdA: 22.9	2y7jB-5lxdA: 25.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 163 ALA A 176 ILE A 212 PHE A 228 LEU A 230 ASP A 295	7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-4.8A) 7A7 A 501 (-3.7A) None 7A7 A 501 (-3.2A)	0.72A	2y7jB-5lxdA: 22.9	2y7jB-5lxdA: 25.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 98 VAL A 106 ALA A 119 MET A 172 GLY A 175 LEU A 221	None	0.57A	2y7jB-5u7qA: 29.0	2y7jB-5u7qA: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ILE A 197 VAL A 205 ALA A 218 LEU A 273 MET A 274 GLY A 277 LEU A 324	QRW A 601 (-4.7A) QRW A 601 (-4.7A) QRW A 601 (-3.4A) None MES A 604 (-3.9A) None None	0.68A	2y7jB-5uuuA: 31.0	2y7jB-5uuuA: 23.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ILE A 197 VAL A 205 ALA A 218 LEU A 273 MET A 274 LEU A 324 ASP A 335	QRW A 601 (-4.7A) QRW A 601 (-4.7A) QRW A 601 (-3.4A) None MES A 604 (-3.9A) None QRW A 601 (-3.7A)	0.85A	2y7jB-5uuuA: 31.0	2y7jB-5uuuA: 23.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	no annotation	6	ILE A 327 VAL A 335 ALA A 348 GLY A 401 LEU A 447 ASP A 458	M77 A 601 ( 4.8A) M77 A 601 (-4.5A) M77 A 601 ( 3.5A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A) M77 A 601 ( 3.5A)	0.64A	2y7jB-5vefA: 30.4	2y7jB-5vefA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5y86	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 3 (Homo sapiens)	no annotation	7	ILE A 215 VAL A 223 ALA A 236 ILE A 272 PHE A 288 LEU A 290 ASP A 355	None HRM A 601 ( 4.9A) HRM A 601 (-3.5A) HRM A 601 ( 4.8A) HRM A 601 (-3.6A) HRM A 601 (-4.6A) HRM A 601 (-4.7A)	0.70A	2y7jB-5y86A: 26.3	2y7jB-5y86A: 12.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5y86	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 3 (Homo sapiens)	no annotation	7	ILE A 215 VAL A 223 ALA A 236 ILE A 272 PHE A 288 LEU A 290 LEU A 342	None HRM A 601 ( 4.9A) HRM A 601 (-3.5A) HRM A 601 ( 4.8A) HRM A 601 (-3.6A) HRM A 601 (-4.6A) None	0.46A	2y7jB-5y86A: 26.3	2y7jB-5y86A: 12.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	6	ILE A 733 VAL A 741 ALA A 754 PHE A 813 MET A 816 LEU A 866	CJM A1102 (-3.4A) None CJM A1102 (-3.1A) CJM A1102 ( 4.4A) None CJM A1102 (-4.4A)	0.54A	2y7jB-6b3eA: 29.2	2y7jB-6b3eA: 11.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	6	ILE A 218 VAL A 226 ALA A 237 GLY A 294 LEU A 347 ASP A 358	DL1 A 601 (-4.0A) None DL1 A 601 (-3.4A) DL1 A 601 (-3.5A) DL1 A 601 (-3.9A) DL1 A 601 (-3.1A)	0.59A	2y7jB-6bfnA: 23.8	2y7jB-6bfnA: 13.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	ILE A 171 VAL A 179 ALA A 192 PHE A 267 LEU A 269 GLY A 273 LEU A 319	BI9 A 501 (-4.0A) BI9 A 501 ( 4.8A) BI9 A 501 (-3.3A) BI9 A 501 ( 4.2A) BI9 A 501 (-4.4A) BI9 A 501 (-3.3A) BI9 A 501 (-4.7A)	0.39A	2y7jB-6bqlA: 31.7	2y7jB-6bqlA: 12.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	6	ILE A 134 VAL A 142 ALA A 155 PHE A 230 LEU A 232 ASP A 293	H1N A 501 (-4.3A) H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-3.7A) H1N A 501 (-4.3A) H1N A 501 (-3.5A)	0.60A	2y7jB-6ccfA: 31.2	2y7jB-6ccfA: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	ILE A 134 VAL A 142 ALA A 155 PHE A 230 LEU A 232 GLY A 236 LEU A 282	H1N A 501 (-4.3A) H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-3.7A) H1N A 501 (-4.3A) H1N A 501 (-3.6A) H1N A 501 (-4.8A)	0.43A	2y7jB-6ccfA: 31.2	2y7jB-6ccfA: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	ILE A 171 VAL A 179 ALA A 192 PHE A 267 LEU A 269 ASP A 330	F6J A 501 (-4.3A) F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-3.7A) F6J A 501 ( 4.4A) F6J A 501 (-3.8A)	0.69A	2y7jB-6cmjA: 30.9	2y7jB-6cmjA: 13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	ILE A 171 VAL A 179 ALA A 192 PHE A 267 LEU A 269 GLY A 273 LEU A 319	F6J A 501 (-4.3A) F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-3.7A) F6J A 501 ( 4.4A) F6J A 501 ( 3.7A) F6J A 501 (-4.5A)	0.55A	2y7jB-6cmjA: 30.9	2y7jB-6cmjA: 13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	6	VAL A 205 ALA A 217 LEU A 266 MET A 267 GLY A 270 LEU A 319	FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-4.4A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.52A	2y7jB-6cz4A: 18.3	2y7jB-6cz4A: 14.16

[["2Y7J_B_B49B1294_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.55A","2y7jB-1k2pA:19.9","2y7jB-1k2pA:22.65"],["2Y7J_B_B49B1294_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321","None","0.53A","2y7jB-1k9aA:26.1","2y7jB-1k9aA:23.51"],["2Y7J_B_B49B1294_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;MET A 269;LEU A 321;ASP A 332","None","0.82A","2y7jB-1k9aA:26.1","2y7jB-1k9aA:23.51"],["2Y7J_B_B49B1294_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",7,"ILE A 580;VAL A 588;ALA A 606;PHE A 654;MET A 657;GLY A 660;LEU A 731","None","0.92A","2y7jB-1lufA:24.6","2y7jB-1lufA:24.10"],["2Y7J_B_B49B1294_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"ILE A 211;VAL A 219;ALA A 230;GLY A 286;LEU A 340;ASP A 351","PY1 A 700 (-3.6A);PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.6A);PY1 A 700 (-4.4A);PY1 A 700 (-2.7A)","0.53A","2y7jB-1py5A:18.8","2y7jB-1py5A:24.88"],["2Y7J_B_B49B1294_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",8,"ILE A 369;VAL A 377;ALA A 389;PHE A 435;MET A 438;GLY A 441;LEU A 489;ASP A 500","None","0.83A","2y7jB-1snxA:24.3","2y7jB-1snxA:22.83"],["2Y7J_B_B49B1294_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;ILE A  89;GLY A 110;LEU A 158","None","0.54A","2y7jB-1u5qA:30.0","2y7jB-1u5qA:25.83"],["2Y7J_B_B49B1294_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;ILE A  89;LEU A 158;ASP A 169","None","0.80A","2y7jB-1u5qA:30.0","2y7jB-1u5qA:25.83"],["2Y7J_B_B49B1294_1","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",6,"VAL A  26;ALA A  39;ILE A  75;PHE A  91;MET A  94;LEU A 144","ATP A 381 (-4.0A);ATP A 381 (-3.6A);None;None;None;None","0.55A","2y7jB-1ua2A:23.3","2y7jB-1ua2A:26.29"],["2Y7J_B_B49B1294_1","2ac5","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","PF00069(Pkinase)",6,"VAL A  98;ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.63A","2y7jB-2ac5A:20.5","2y7jB-2ac5A:29.18"],["2Y7J_B_B49B1294_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"VAL A  27;ALA A  40;ILE A  72;LEU A  95;MET A  96;LEU A 144","ADP A 500 (-4.3A);ADP A 500 ( 3.7A);None;ADP A 500 ( 4.9A);None;ADP A 500 (-4.3A)","0.27A","2y7jB-2f9gA:20.6","2y7jB-2f9gA:25.64"],["2Y7J_B_B49B1294_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;ILE A  89;GLY A 110;LEU A 158","STU A 400 (-4.2A);STU A 400 ( 4.8A);STU A 400 (-3.2A);STU A 400 ( 4.5A);STU A 400 (-3.4A);STU A 400 ( 4.6A)","0.56A","2y7jB-2gcdA:31.2","2y7jB-2gcdA:23.65"],["2Y7J_B_B49B1294_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"ILE A 635;VAL A 643;ALA A 659;ILE A 691;MET A 710;GLY A 713;LEU A 761","ADP A 400 (-4.9A);ADP A 400 ( 4.4A);ADP A 400 (-3.2A);None;None;ADP A 400 ( 4.2A);ADP A 400 ( 4.7A)","0.64A","2y7jB-2henA:13.4","2y7jB-2henA:20.21"],["2Y7J_B_B49B1294_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LEU A 501;GLY A 505;LEU A 553","4ST A1687 (-4.2A);4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-4.3A);4ST A1687 (-3.2A);4ST A1687 (-4.4A)","0.60A","2y7jB-2j0jA:24.6","2y7jB-2j0jA:19.64"],["2Y7J_B_B49B1294_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LEU A 501;GLY A 505;LEU A 553","BII A1687 (-3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);BII A1687 (-4.4A);BII A1687 (-3.6A);BII A1687 (-4.2A)","0.69A","2y7jB-2jkmA:24.4","2y7jB-2jkmA:22.80"],["2Y7J_B_B49B1294_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",8,"VAL A  33;ALA A  46;ILE A  87;PHE A 103;LEU A 105;MET A 106;GLY A 109;LEU A 156","ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;None;None;None;ATP A 381 ( 4.8A)","0.28A","2y7jB-2phkA:38.1","2y7jB-2phkA:53.78"],["2Y7J_B_B49B1294_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"VAL A 495;ALA A 515;ILE A 548;GLY A 570;LEU A 633;ASP A 644","None","0.65A","2y7jB-2psqA:27.1","2y7jB-2psqA:24.82"],["2Y7J_B_B49B1294_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"ILE B  47;VAL B  55;ALA B  67;MET B 117;GLY B 120;LEU B 171","None","0.42A","2y7jB-2qkwB:25.7","2y7jB-2qkwB:27.45"],["2Y7J_B_B49B1294_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;ILE A 683;MET A 702;GLY A 705;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;PTR A 701 ( 3.5A);None;None","0.59A","2y7jB-2qobA:20.0","2y7jB-2qobA:20.05"],["2Y7J_B_B49B1294_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ILE A 681;VAL A 689;ALA A 705;ILE A 737;MET A 756;GLY A 759;LEU A 807","None","0.78A","2y7jB-2r2pA:27.3","2y7jB-2r2pA:21.75"],["2Y7J_B_B49B1294_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"VAL A 732;ALA A 749;LEU A 798;MET A 799;GLY A 802;LEU A 850","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-4.5A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.59A","2y7jB-2r4bA:23.1","2y7jB-2r4bA:24.24"],["2Y7J_B_B49B1294_1","2vuw","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE HASPIN","PF12330(Haspin_kinase)",6,"ILE A 490;VAL A 498;ALA A 509;ILE A 557;PHE A 605;LEU A 656","None;5ID A1800 ( 4.5A);5ID A1800 (-3.4A);5ID A1800 ( 4.5A);5ID A1800 (-4.1A);5ID A1800 (-4.5A)","0.49A","2y7jB-2vuwA:18.9","2y7jB-2vuwA:22.33"],["2Y7J_B_B49B1294_1","2wnt","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE","PF00069(Pkinase)",6,"ILE A 424;ALA A 445;ILE A 473;LEU A 491;MET A 492;ASP A 557","None","0.78A","2y7jB-2wntA:26.1","2y7jB-2wntA:32.21"],["2Y7J_B_B49B1294_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"VAL A 234;ALA A 247;ILE A 286;LEU A 303;MET A 304;GLY A 307;LEU A 354","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);None;XK9 A1511 (-4.1A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A)","0.37A","2y7jB-2xk9A:29.5","2y7jB-2xk9A:31.30"],["2Y7J_B_B49B1294_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",7,"ILE A 627;VAL A 635;ALA A 651;ILE A 683;MET A 702;GLY A 705;LEU A 753","None;Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 ( 4.9A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.58A","2y7jB-2xyuA:18.8","2y7jB-2xyuA:22.37"],["2Y7J_B_B49B1294_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1010;ALA A1028;LEU A1078;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-4.7A);None;S91 A   1 (-3.3A);None","0.71A","2y7jB-2z8cA:26.9","2y7jB-2z8cA:24.56"],["2Y7J_B_B49B1294_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"VAL A 495;ALA A 515;ILE A 548;GLY A 570;LEU A 633;ASP A 644","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;M33 A1996 ( 4.8A);M33 A1996 (-4.5A);M33 A1996 (-4.0A)","0.43A","2y7jB-3b2tA:22.8","2y7jB-3b2tA:22.96"],["2Y7J_B_B49B1294_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",6,"ILE A  18;VAL A  26;ALA A  39;PHE A  91;MET A  94;LEU A 148","3AM A 338 (-4.5A);3AM A 338 ( 4.1A);3AM A 338 (-3.3A);3AM A 338 (-3.6A);None;3AM A 338 (-4.7A)","0.77A","2y7jB-3c0iA:32.8","2y7jB-3c0iA:28.54"],["2Y7J_B_B49B1294_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 492;ALA A 512;ILE A 545;GLY A 567;LEU A 630;ASP A 641","None;C4F A   1 (-3.3A);C4F A   1 ( 4.0A);None;C4F A   1 (-4.6A);C4F A   1 (-4.5A)","0.82A","2y7jB-3c4fA:23.6","2y7jB-3c4fA:24.43"],["2Y7J_B_B49B1294_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321","None","0.53A","2y7jB-3d7uA:26.9","2y7jB-3d7uA:22.02"],["2Y7J_B_B49B1294_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;MET A 269;LEU A 321;ASP A 332","None","0.82A","2y7jB-3d7uA:26.9","2y7jB-3d7uA:22.02"],["2Y7J_B_B49B1294_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"ILE A  23;VAL A  31;ALA A  44;LEU A  94;LEU A 153;ASP A 164","ANP A   1 (-4.2A);ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None;ANP A   1 (-3.8A)","0.81A","2y7jB-3dakA:25.0","2y7jB-3dakA:26.77"],["2Y7J_B_B49B1294_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ILE A 639;VAL A 647;ALA A 663;MET A 714;GLY A 717;LEU A 765","IHZ A1001 ( 4.8A);IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);None;IHZ A1001 ( 3.9A);IHZ A1001 (-4.6A)","0.63A","2y7jB-3dkoA:23.4","2y7jB-3dkoA:21.76"],["2Y7J_B_B49B1294_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",6,"ILE A 150;VAL A 158;ALA A 169;ILE A 204;GLY A 226;LEU A 275","VIN A6331 (-4.0A);VIN A6331 (-4.7A);VIN A6331 (-3.4A);VIN A6331 ( 4.9A);VIN A6331 (-3.4A);VIN A6331 (-4.5A)","0.39A","2y7jB-3dtcA:23.7","2y7jB-3dtcA:23.59"],["2Y7J_B_B49B1294_1","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",6,"ILE A  32;VAL A  40;ALA A  53;ILE A  86;LEU A 110;MET A 111","35F A   1 ( 4.4A);35F A   1 ( 4.8A);35F A   1 (-3.6A);None;35F A   1 (-4.5A);None","0.39A","2y7jB-3e7oA:24.1","2y7jB-3e7oA:23.52"],["2Y7J_B_B49B1294_1","3f3z","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;ILE A  86;LEU A 104;LEU A 155","DRK A   1 (-4.2A);DRK A   1 ( 4.9A);DRK A   1 (-3.4A);DRK A   1 ( 4.8A);DRK A   1 (-4.4A);DRK A   1 (-4.6A)","0.59A","2y7jB-3f3zA:35.0","2y7jB-3f3zA:27.60"],["2Y7J_B_B49B1294_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",7,"ALA A 247;ILE A 286;LEU A 303;MET A 304;GLY A 307;LEU A 354;ASP A 368","None","0.80A","2y7jB-3i6uA:28.0","2y7jB-3i6uA:30.75"],["2Y7J_B_B49B1294_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",7,"VAL A 234;ALA A 247;ILE A 286;LEU A 303;MET A 304;LEU A 354;ASP A 368","None","0.84A","2y7jB-3i6uA:28.0","2y7jB-3i6uA:30.75"],["2Y7J_B_B49B1294_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;ILE A 697;MET A 716;GLY A 719;LEU A 767;ASP A 778","None;None;None;None;GOL A 403 (-3.4A);None;None","0.93A","2y7jB-3kulA:27.4","2y7jB-3kulA:26.12"],["2Y7J_B_B49B1294_1","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",6,"VAL A  47;ALA A  60;ILE A  94;GLY A 116;LEU A 165;ASP A 179","QUE A   1 ( 4.6A);QUE A   1 (-3.2A);QUE A   1 (-4.6A);None;None;QUE A   1 (-2.9A)","0.79A","2y7jB-3lm5A:31.9","2y7jB-3lm5A:30.81"],["2Y7J_B_B49B1294_1","3n9x","Plasmodium berghei","PHOSPHOTRANSFERASE","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;ILE A  88;LEU A 161;ASP A 172","GOL A 434 ( 4.5A);None;GOL A 434 ( 4.1A);None;GOL A 434 (-4.2A);GOL A 433 (-2.7A)","0.64A","2y7jB-3n9xA:24.1","2y7jB-3n9xA:24.95"],["2Y7J_B_B49B1294_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"VAL A 200;ALA A 213;LEU A 265;MET A 266;GLY A 269;LEU A 318","AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 ( 4.9A);None;None;AMP A 577 (-4.8A)","0.37A","2y7jB-3nyoA:30.6","2y7jB-3nyoA:24.72"],["2Y7J_B_B49B1294_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"VAL A 734;ALA A 751;LEU A 800;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.6A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.45A","2y7jB-3pp0A:25.4","2y7jB-3pp0A:21.57"],["2Y7J_B_B49B1294_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",6,"ILE A 557;VAL A 565;ALA A 576;GLY A 631;LEU A 683;ASP A 694","STU A   1 (-4.1A);STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A)","0.70A","2y7jB-3ppzA:29.3","2y7jB-3ppzA:28.86"],["2Y7J_B_B49B1294_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 492;ALA A 512;ILE A 545;GLY A 567;LEU A 630;ASP A 641","07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.7A);07J A   1 ( 4.4A);07J A   1 (-4.7A)","0.82A","2y7jB-3tt0A:18.0","2y7jB-3tt0A:25.35"],["2Y7J_B_B49B1294_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 552;ALA A 570;PHE A 617;MET A 620;GLY A 623;LEU A 686","None;0F4 A 902 (-3.2A);0F4 A 902 (-3.4A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.37A","2y7jB-3v5qA:18.5","2y7jB-3v5qA:25.79"],["2Y7J_B_B49B1294_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"VAL A  67;ALA A  80;LEU A 131;MET A 132;LEU A 186;ASP A 197","ANK A 401 (-4.3A);ANK A 401 (-3.0A);None;None;ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.78A","2y7jB-3vn9A:24.1","2y7jB-3vn9A:24.60"],["2Y7J_B_B49B1294_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"VAL A  83;ALA A  96;MET A 147;GLY A 150;LEU A 198;ASP A 209","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.75A","2y7jB-3wigA:19.3","2y7jB-3wigA:23.72"],["2Y7J_B_B49B1294_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.64A","2y7jB-3zbfA:21.0","2y7jB-3zbfA:24.31"],["2Y7J_B_B49B1294_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"VAL A1959;ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.38A","2y7jB-3zbfA:21.0","2y7jB-3zbfA:24.31"],["2Y7J_B_B49B1294_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"ILE A 625;VAL A 633;ALA A 649;ILE A 681;MET A 700;GLY A 703;LEU A 751;ASP A 762","None","0.60A","2y7jB-3zfxA:26.8","2y7jB-3zfxA:22.99"],["2Y7J_B_B49B1294_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 568;ALA A 586;PHE A 633;MET A 636;GLY A 639;LEU A 699","None;LTI A1839 (-3.3A);LTI A1839 (-3.5A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.43A","2y7jB-4at3A:18.0","2y7jB-4at3A:23.28"],["2Y7J_B_B49B1294_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"ILE A  97;VAL A 105;ALA A 121;ILE A 153;MET A 172;GLY A 175;LEU A 223;ASP A 234","30K A1365 (-4.5A);30K A1365 ( 4.6A);30K A1365 (-3.2A);None;None;30K A1365 (-3.5A);30K A1365 (-4.5A);30K A1365 (-3.3A)","0.63A","2y7jB-4aw5A:20.2","2y7jB-4aw5A:27.52"],["2Y7J_B_B49B1294_1","4b99","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 7","PF00069(Pkinase)",7,"ILE A  61;VAL A  69;ALA A  82;ILE A 115;LEU A 139;MET A 140;LEU A 189","R4L A1394 (-4.0A);R4L A1394 (-4.0A);R4L A1394 ( 3.7A);R4L A1394 (-4.9A);R4L A1394 ( 4.9A);None;R4L A1394 (-4.5A)","0.68A","2y7jB-4b99A:26.7","2y7jB-4b99A:25.65"],["2Y7J_B_B49B1294_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A 254;ALA A 267;ILE A 302;GLY A 324;LEU A 371;ASP A 382","None","0.77A","2y7jB-4c0tA:29.6","2y7jB-4c0tA:17.15"],["2Y7J_B_B49B1294_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"ILE A 567;VAL A 575;ALA A 588;LEU A 638;GLY A 642;LEU A 690","GUI A 901 (-4.0A);GUI A 901 (-4.5A);GUI A 901 (-3.4A);GUI A 901 (-4.4A);GUI A 901 (-3.5A);GUI A 901 (-4.3A)","0.57A","2y7jB-4e93A:20.4","2y7jB-4e93A:25.60"],["2Y7J_B_B49B1294_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 523;ALA A 541;PHE A 588;MET A 591;GLY A 594;LEU A 656","None","0.40A","2y7jB-4f0iA:17.2","2y7jB-4f0iA:22.76"],["2Y7J_B_B49B1294_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A1130;ALA A1148;LEU A1198;MET A1199;GLY A1202;LEU A1256;ASP A1270","0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.8A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A);0UV A1501 ( 4.2A)","0.62A","2y7jB-4fodA:24.3","2y7jB-4fodA:23.27"],["2Y7J_B_B49B1294_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",6,"ILE A  29;VAL A  37;ALA A  50;LEU A 102;GLY A 106;LEU A 153","STU A 401 (-4.1A);STU A 401 ( 4.9A);STU A 401 (-3.2A);STU A 401 (-4.4A);STU A 401 ( 3.7A);STU A 401 (-4.7A)","0.57A","2y7jB-4fr4A:29.8","2y7jB-4fr4A:21.02"],["2Y7J_B_B49B1294_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ASP A 404","0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.1A)","0.70A","2y7jB-4k11A:24.3","2y7jB-4k11A:24.41"],["2Y7J_B_B49B1294_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",6,"ILE A 413;VAL A 421;ALA A 434;GLY A 487;LEU A 533;ASP A 544","B49 A 701 (-4.2A);None;B49 A 701 (-3.2A);B49 A 701 ( 3.7A);B49 A 701 (-4.5A);B49 A 701 (-4.6A)","0.46A","2y7jB-4ks8A:30.9","2y7jB-4ks8A:26.70"],["2Y7J_B_B49B1294_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ASP A 404","VGG A 601 ( 3.5A);VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.7A)","0.40A","2y7jB-4lggA:23.8","2y7jB-4lggA:24.93"],["2Y7J_B_B49B1294_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",7,"ILE A 197;VAL A 205;ALA A 218;LEU A 273;MET A 274;GLY A 276;LEU A 324","29X A 702 (-4.7A);29X A 702 (-4.7A);29X A 702 (-3.1A);29X A 702 (-4.6A);None;None;29X A 702 (-4.6A)","0.85A","2y7jB-4mk0A:30.9","2y7jB-4mk0A:20.80"],["2Y7J_B_B49B1294_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",7,"ILE A 197;VAL A 205;ALA A 218;LEU A 273;MET A 274;LEU A 324;ASP A 335","29X A 702 (-4.7A);29X A 702 (-4.7A);29X A 702 (-3.1A);29X A 702 (-4.6A);None;29X A 702 (-4.6A);29X A 702 (-4.4A)","0.88A","2y7jB-4mk0A:30.9","2y7jB-4mk0A:20.80"],["2Y7J_B_B49B1294_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",6,"ILE A 197;VAL A 205;ALA A 218;MET A 274;GLY A 277;LEU A 324","29X A 702 (-4.7A);29X A 702 (-4.7A);29X A 702 (-3.1A);None;None;29X A 702 (-4.6A)","0.72A","2y7jB-4mk0A:30.9","2y7jB-4mk0A:20.80"],["2Y7J_B_B49B1294_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 644;ILE A 676;MET A 695;GLY A 698;LEU A 746;ASP A 757","None","0.59A","2y7jB-4p2kA:26.9","2y7jB-4p2kA:24.93"],["2Y7J_B_B49B1294_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ILE A 619;VAL A 627;ALA A 644;ILE A 676;MET A 695;GLY A 698;LEU A 746","None","0.64A","2y7jB-4p2kA:26.9","2y7jB-4p2kA:24.93"],["2Y7J_B_B49B1294_1","4qny","Leishmania donovani","MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE","PF00069(Pkinase)",6,"ILE A  27;VAL A  35;ALA A  49;ILE A  83;MET A 107;LEU A 156","ANP A 402 (-4.6A);ANP A 402 (-4.3A);ANP A 402 (-3.3A);ANP A 402 (-4.8A);None;ANP A 402 (-4.6A)","0.37A","2y7jB-4qnyA:28.2","2y7jB-4qnyA:23.65"],["2Y7J_B_B49B1294_1","4qtb","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",7,"ILE A  48;VAL A  56;ALA A  69;ILE A 101;LEU A 124;MET A 125;LEU A 173","38Z A 418 ( 4.4A);None;38Z A 418 (-3.4A);38Z A 418 ( 4.9A);38Z A 418 ( 4.8A);None;38Z A 418 (-4.4A)","0.46A","2y7jB-4qtbA:21.1","2y7jB-4qtbA:27.85"],["2Y7J_B_B49B1294_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",7,"ILE A 150;VAL A 158;ALA A 169;ILE A 204;GLY A 226;LEU A 275;ASP A 294","None","1.02A","2y7jB-4uy9A:22.8","2y7jB-4uy9A:23.70"],["2Y7J_B_B49B1294_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.68A","2y7jB-4xi2A:23.7","2y7jB-4xi2A:22.78"],["2Y7J_B_B49B1294_1","4xrl","Rattus norvegicus","MITOGEN-ACTIVATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ILE A  29;VAL A  37;ALA A  50;ILE A  82;LEU A 105;MET A 106;LEU A 154","42A A 402 ( 4.7A);None;42A A 402 (-3.2A);None;42A A 402 ( 4.9A);None;42A A 402 ( 4.9A)","0.58A","2y7jB-4xrlA:28.1","2y7jB-4xrlA:24.57"],["2Y7J_B_B49B1294_1","4z7g","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"VAL A 586;ALA A 597;ILE A 626;LEU A 644;LEU A 695;ASP A 711","None","0.80A","2y7jB-4z7gA:22.6","2y7jB-4z7gA:22.04"],["2Y7J_B_B49B1294_1","4zsl","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 7","PF00069(Pkinase)",7,"ILE A  61;VAL A  69;ALA A  82;ILE A 115;LEU A 139;MET A 140;LEU A 189","None","0.63A","2y7jB-4zslA:26.1","2y7jB-4zslA:26.99"],["2Y7J_B_B49B1294_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"VAL A 492;ALA A 512;ILE A 545;GLY A 567;LEU A 630;ASP A 641","38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.3A);38O A1769 (-3.4A);38O A1769 (-4.6A);38O A1769 (-4.0A)","0.63A","2y7jB-5a46A:23.8","2y7jB-5a46A:23.64"],["2Y7J_B_B49B1294_1","5awm","Drosophila melanogaster","STRESS-ACTIVATED PROTEIN KINASE JNK","PF00069(Pkinase)",6,"ILE A  30;VAL A  38;ALA A  51;ILE A  84;LEU A 108;MET A 109","ANP A 401 (-4.9A);ANP A 401 (-4.5A);ANP A 401 (-3.5A);None;ANP A 401 ( 4.8A);None","0.46A","2y7jB-5awmA:23.3","2y7jB-5awmA:23.23"],["2Y7J_B_B49B1294_1","5ci6","Arabidopsis thaliana","MITOGEN-ACTIVATED PROTEIN KINASE 6","PF00069(Pkinase)",6,"ILE A  69;VAL A  77;ALA A  90;LEU A 146;MET A 147;LEU A 196","None","0.56A","2y7jB-5ci6A:24.7","2y7jB-5ci6A:23.39"],["2Y7J_B_B49B1294_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"ILE A  22;VAL A  30;ALA A  44;GLY A  98;LEU A 145;ASP A 165","51W A 401 (-3.9A);51W A 401 ( 4.3A);51W A 401 (-3.4A);51W A 401 (-3.7A);51W A 401 (-4.5A);GOL A 404 (-3.2A)","0.79A","2y7jB-5ci7A:26.7","2y7jB-5ci7A:26.33"],["2Y7J_B_B49B1294_1","5ezr","Plasmodium vivax","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","PF00027(cNMP_binding);PF00069(Pkinase)",6,"ILE A 540;VAL A 548;ALA A 561;ILE A 595;LEU A 613;ASP A 675","4ZS A 901 (-4.2A);4ZS A 901 (-4.8A);4ZS A 901 ( 3.8A);4ZS A 901 (-4.3A);4ZS A 901 (-4.7A);None","0.67A","2y7jB-5ezrA:27.7","2y7jB-5ezrA:18.73"],["2Y7J_B_B49B1294_1","5ezr","Plasmodium vivax","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","PF00027(cNMP_binding);PF00069(Pkinase)",6,"ILE A 540;VAL A 548;ALA A 561;ILE A 595;LEU A 613;LEU A 664","4ZS A 901 (-4.2A);4ZS A 901 (-4.8A);4ZS A 901 ( 3.8A);4ZS A 901 (-4.3A);4ZS A 901 (-4.7A);4ZS A 901 (-3.6A)","0.51A","2y7jB-5ezrA:27.7","2y7jB-5ezrA:18.73"],["2Y7J_B_B49B1294_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",6,"VAL A  28;ALA A  41;PHE A  90;LEU A  92;GLY A  96;LEU A 143","ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;ADP A 301 ( 4.8A);None;ADP A 301 (-4.7A)","0.38A","2y7jB-5hu3A:36.3","2y7jB-5hu3A:34.16"],["2Y7J_B_B49B1294_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 726;ALA A 743;LEU A 792;MET A 793;GLY A 796;LEU A 844;ASP A 855","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 ( 4.9A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A);6HJ A1101 (-4.3A)","0.35A","2y7jB-5j9zA:24.9","2y7jB-5j9zA:23.47"],["2Y7J_B_B49B1294_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"ILE A 396;VAL A 404;ALA A 417;LEU A 467;GLY A 471;LEU A 518","GUI A 701 (-4.1A);GUI A 701 (-4.4A);GUI A 701 ( 3.9A);GUI A 701 ( 4.7A);GUI A 701 (-3.6A);GUI A 701 (-4.4A)","0.46A","2y7jB-5jznA:35.1","2y7jB-5jznA:31.03"],["2Y7J_B_B49B1294_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",7,"ILE A 155;VAL A 163;ALA A 176;ILE A 212;PHE A 228;LEU A 230;LEU A 282","7A7 A 501 ( 4.3A);7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-4.8A);7A7 A 501 (-3.7A);None;7A7 A 501 (-4.9A)","0.84A","2y7jB-5lxdA:22.9","2y7jB-5lxdA:25.23"],["2Y7J_B_B49B1294_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",6,"VAL A 163;ALA A 176;ILE A 212;PHE A 228;LEU A 230;ASP A 295","7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-4.8A);7A7 A 501 (-3.7A);None;7A7 A 501 (-3.2A)","0.72A","2y7jB-5lxdA:22.9","2y7jB-5lxdA:25.23"],["2Y7J_B_B49B1294_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"ILE A  98;VAL A 106;ALA A 119;MET A 172;GLY A 175;LEU A 221","None","0.57A","2y7jB-5u7qA:29.0","2y7jB-5u7qA:24.94"],["2Y7J_B_B49B1294_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",7,"ILE A 197;VAL A 205;ALA A 218;LEU A 273;MET A 274;GLY A 277;LEU A 324","QRW A 601 (-4.7A);QRW A 601 (-4.7A);QRW A 601 (-3.4A);None;MES A 604 (-3.9A);None;None","0.68A","2y7jB-5uuuA:31.0","2y7jB-5uuuA:23.69"],["2Y7J_B_B49B1294_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",7,"ILE A 197;VAL A 205;ALA A 218;LEU A 273;MET A 274;LEU A 324;ASP A 335","QRW A 601 (-4.7A);QRW A 601 (-4.7A);QRW A 601 (-3.4A);None;MES A 604 (-3.9A);None;QRW A 601 (-3.7A)","0.85A","2y7jB-5uuuA:31.0","2y7jB-5uuuA:23.69"],["2Y7J_B_B49B1294_1","5vef","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","no annotation",6,"ILE A 327;VAL A 335;ALA A 348;GLY A 401;LEU A 447;ASP A 458","M77 A 601 ( 4.8A);M77 A 601 (-4.5A);M77 A 601 ( 3.5A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A);M77 A 601 ( 3.5A)","0.64A","2y7jB-5vefA:30.4","2y7jB-5vefA:26.30"],["2Y7J_B_B49B1294_1","5y86","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 3","no annotation",7,"ILE A 215;VAL A 223;ALA A 236;ILE A 272;PHE A 288;LEU A 290;ASP A 355","None;HRM A 601 ( 4.9A);HRM A 601 (-3.5A);HRM A 601 ( 4.8A);HRM A 601 (-3.6A);HRM A 601 (-4.6A);HRM A 601 (-4.7A)","0.70A","2y7jB-5y86A:26.3","2y7jB-5y86A:12.88"],["2Y7J_B_B49B1294_1","5y86","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 3","no annotation",7,"ILE A 215;VAL A 223;ALA A 236;ILE A 272;PHE A 288;LEU A 290;LEU A 342","None;HRM A 601 ( 4.9A);HRM A 601 (-3.5A);HRM A 601 ( 4.8A);HRM A 601 (-3.6A);HRM A 601 (-4.6A);None","0.46A","2y7jB-5y86A:26.3","2y7jB-5y86A:12.88"],["2Y7J_B_B49B1294_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",6,"ILE A 733;VAL A 741;ALA A 754;PHE A 813;MET A 816;LEU A 866","CJM A1102 (-3.4A);None;CJM A1102 (-3.1A);CJM A1102 ( 4.4A);None;CJM A1102 (-4.4A)","0.54A","2y7jB-6b3eA:29.2","2y7jB-6b3eA:11.82"],["2Y7J_B_B49B1294_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",6,"ILE A 218;VAL A 226;ALA A 237;GLY A 294;LEU A 347;ASP A 358","DL1 A 601 (-4.0A);None;DL1 A 601 (-3.4A);DL1 A 601 (-3.5A);DL1 A 601 (-3.9A);DL1 A 601 (-3.1A)","0.59A","2y7jB-6bfnA:23.8","2y7jB-6bfnA:13.20"],["2Y7J_B_B49B1294_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"ILE A 171;VAL A 179;ALA A 192;PHE A 267;LEU A 269;GLY A 273;LEU A 319","BI9 A 501 (-4.0A);BI9 A 501 ( 4.8A);BI9 A 501 (-3.3A);BI9 A 501 ( 4.2A);BI9 A 501 (-4.4A);BI9 A 501 (-3.3A);BI9 A 501 (-4.7A)","0.39A","2y7jB-6bqlA:31.7","2y7jB-6bqlA:12.00"],["2Y7J_B_B49B1294_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",6,"ILE A 134;VAL A 142;ALA A 155;PHE A 230;LEU A 232;ASP A 293","H1N A 501 (-4.3A);H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-3.7A);H1N A 501 (-4.3A);H1N A 501 (-3.5A)","0.60A","2y7jB-6ccfA:31.2","2y7jB-6ccfA:14.29"],["2Y7J_B_B49B1294_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"ILE A 134;VAL A 142;ALA A 155;PHE A 230;LEU A 232;GLY A 236;LEU A 282","H1N A 501 (-4.3A);H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-3.7A);H1N A 501 (-4.3A);H1N A 501 (-3.6A);H1N A 501 (-4.8A)","0.43A","2y7jB-6ccfA:31.2","2y7jB-6ccfA:14.29"],["2Y7J_B_B49B1294_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"ILE A 171;VAL A 179;ALA A 192;PHE A 267;LEU A 269;ASP A 330","F6J A 501 (-4.3A);F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-3.7A);F6J A 501 ( 4.4A);F6J A 501 (-3.8A)","0.69A","2y7jB-6cmjA:30.9","2y7jB-6cmjA:13.85"],["2Y7J_B_B49B1294_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"ILE A 171;VAL A 179;ALA A 192;PHE A 267;LEU A 269;GLY A 273;LEU A 319","F6J A 501 (-4.3A);F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-3.7A);F6J A 501 ( 4.4A);F6J A 501 ( 3.7A);F6J A 501 (-4.5A)","0.55A","2y7jB-6cmjA:30.9","2y7jB-6cmjA:13.85"],["2Y7J_B_B49B1294_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",6,"VAL A 205;ALA A 217;LEU A 266;MET A 267;GLY A 270;LEU A 319","FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-4.4A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.52A","2y7jB-6cz4A:18.3","2y7jB-6cz4A:14.16"]]